https://doi.org/10.4081/reumatismo.2019.1115
Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
Submitted: 31 December 2017
Accepted: 6 September 2018
Published: 9 July 2019
Accepted: 6 September 2018
Abstract Views: 1127
PDF: 705
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far.
How to Cite
Shobha, V., Desai, A., & Matthew, T. (2019). Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case. Reumatismo, 71(2), 99–102. https://doi.org/10.4081/reumatismo.2019.1115
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- C. Pizzorni, M.E. Secchi, M. Cutolo, Leishmaniasis in rheumatoid arthritis , Reumatismo: Vol. 59 No. 3 (2007)
- F. Macaluso, G. Guggino, A. Rizzo, A. Ferrante, F. Ciccia, Histopathology of the gut in rheumatic diseases , Reumatismo: Vol. 70 No. 3 (2018): Monographic issue on Histopathology in Rheumatic Diseases
- B. Maranini, G. Ciancio, R. Cultrera, M. Govoni, Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis , Reumatismo: Vol. 73 No. 3 (2021)
- H. Beyaztas, S. Aktas, E.M. Guler, E. Ata, Oxidative stress may be a contributing factor in fibromyalgia patients’ pain mechanisms , Reumatismo: Vol. 75 No. 3 (2023)
- G. Valesini, M. Cutolo, Effects of TNF antagonists on immune and neuroendocrine system , Reumatismo: Vol. 57 No. s4 (2005)
- B. Maranini, G. Ciancio, R. Cultrera, M. Govoni, Reply to: “Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab” by Josef Finsterer , Reumatismo: Vol. 74 No. 1 (2022)
- T. Del Ross, A. Ruffatti, M. Tonello, G. Salmistraro, A. Calligaro, M. Favaro, M. Ciprian, S. Todesco, Primary antiphosholipid syndrome and hyperomocysteinemia: a study of a group of 29 patients , Reumatismo: Vol. 58 No. 4 (2006)
- V. Pengo, A. Ruffatti, Laboratory diagnosis of antiphospholipid syndrome , Reumatismo: Vol. 59 No. 3 (2007)
- S. Zingarelli, P. Airò, M. Frassi, C. Bazzani, M. Scarsi, M. Puoti, Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases , Reumatismo: Vol. 60 No. 1 (2008)
- S. Casigliani Rabl, A. Della Rossa, P. Pepe, A. D'Ascanio, M. Mosca, A. Di Vita, S. Bombardieri, Long-term cyclic intravenous iloprost in systemic sclerosis: clinical experience from a single center , Reumatismo: Vol. 64 No. 3 (2012)
<< < 20 21 22 23 24 25 26 27 28 29 > >>
You may also start an advanced similarity search for this article.
